Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Depression
NCT01392963Phase 2Completed
- Sponsor
- Ascension Seton
- Start
- Jul 2011
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in major depressive disorder (MDD), sponsored by Ascension Seton. Started Jul 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01392963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392963.